ArticleTherapeutic advances in medical oncology2026
Impact of concomitant use of renin-angiotensin system inhibitors on survival in patients with pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and limited therapeutic options, particularly in the metastatic setting. Novel strategies to overcome treatment resistance are highly anticipated and may potentially include the repurposing of existing pharmacologic agents. Objectives: To prove the positive effect of angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) on survival in PDAC. Design: A systematic review and meta-analysis were conducted based on Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Data sources and methods: A systematic search of PubMed, Web of Science, and Cochrane databases was conducted to identify studies evaluating survival outcomes in patients with PDAC receiving concomitant treatment with ARBs or ACEIs. Survival outcomes were analyzed with random-effects models using hazard ratios (HRs) and 95% confidence intervals (CIs) extracted from included trials. Studies without sufficient survival data were reviewed qualitatively only. Results: A total of 14 studies, comprising a total of 19,287 patients, met the inclusion criteria. Results indicated that the concurrent treatment with ACEIs or ARBs in patients with PDAC was associated with significantly improved overall survival compared to no use (HR = 0.80; 95% CI: 0.76-0.86; Conclusion: Our meta-analysis supports the efficacy of renin-angiotensin system inhibitors as concomitant therapy in patients with PDAC. Prospective randomized clinical trials are warranted to validate ACEI/ARB as adjunctive therapy in well-defined PDAC patient populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.